Hellinckx J, De Boeck K, Demedts M
Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium.
Chest. 1998 Jan;113(1):55-9. doi: 10.1378/chest.113.1.55.
The aim of the present study was to evaluate the forced oscillation technique (FOT) in cystic fibrosis (CF) children and to participate in the discussion about the usefulness of beta2-antagonists in CF.
Pulmonary function was measured with spirometry, body plethysmography, and FOT before and after inhalation of 200 microg of albuterol (salbutamol). The following were collected: vital capacity (VC), FEV1, FEV1/VC, airway resistance (Raw), thoracic gas volume, respiratory system resistance (Rrs) and respiratory system reactance (Xrs) at 6 Hz (Rrs6 and Xrs6), and resonance frequency.
The study was set up at a university hospital with a CF population of 125 children and adolescents.
Data were collected on 20 patients in stable condition able to perform the three lung function tests.
Mean baseline values (+/-SD) were 0.36+/-0.15 kPa/L/s for Raw, 0.5+/-0.15 kPa/L/s for Rrs6, and 61+/-22% predicted for FEV1. The relationship between FEV1 and Raw or Rrs6 was poor. Xrs6 and FEV1/VC correlated weakly (r=0.56; p < 0.05). After bronchodilator administration, the mean changes +/-SD in percent of baseline were +3 +/- 11% for FEV1, -16 +/- 22% for Raw, and -16 +/- 9% for Rrs6. In six patients, a paradoxical decrease in FEV1 was measured but an increase in Rrs6 was never found; in two patients, an increase of Raw of < 10% was found. In 13 patients, the decrease of Rrs6 was > 12%.
The results suggest that FOT measurements cannot replace baseline spirometric measurements in CF, but that the evaluation of the effect of beta2-agonists on the airway diameter in CF should include an FOT measurement.
本研究旨在评估强迫振荡技术(FOT)在囊性纤维化(CF)儿童中的应用,并参与关于β2拮抗剂在CF中效用的讨论。
在吸入200微克沙丁胺醇前后,用肺活量测定法、体容积描记法和FOT测量肺功能。收集以下数据:肺活量(VC)、第一秒用力呼气容积(FEV1)、FEV1/VC、气道阻力(Raw)、胸腔气体容积、呼吸系统阻力(Rrs)以及6赫兹时的呼吸系统电抗(Xrs)(Rrs6和Xrs6),还有共振频率。
该研究在一家大学医院开展,该院有125名CF儿童和青少年患者。
收集了20名病情稳定、能够进行三项肺功能测试的患者的数据。
Raw的平均基线值(±标准差)为0.36±0.15千帕/升/秒,Rrs6为0.5±0.15千帕/升/秒,FEV1为预测值的61±22%。FEV1与Raw或Rrs6之间的关系不佳。Xrs6与FEV1/VC的相关性较弱(r = 0.56;p < 0.05)。支气管扩张剂给药后,相对于基线的平均变化(±标准差)百分比为:FEV1为+3±11%,Raw为 -16±22%,Rrs6为 -16±9%。在6名患者中,测量到FEV1出现反常下降,但从未发现Rrs6增加;在2名患者中,发现Raw增加<10%。在13名患者中,Rrs6的下降>12%。
结果表明,FOT测量不能替代CF患者的基线肺量计测量,但对CF患者中β2激动剂对气道直径影响的评估应包括FOT测量。